Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 430Neoplasms, Plasma Cell 58Recurrence 33Smoldering Multiple Myeloma 17Neoplasms 14Hematologic Diseases 11Immunoglobulin Light-chain Amyloidosis 8Leukemia, Plasma Cell 7Paraproteinemias 6Hematologic Neoplasms 6Amyloidosis 6Neoplasm, Residual 5Renal Insufficiency 4Plasmacytoma 4Lymphoma 4Disease Progression 4Disease 4Blood Protein Disorders 4Lymphoma, Non-Hodgkin 3POEMS Syndrome 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Leukemia 2Immunoproliferative Disorders 2Hodgkin Disease 2Corneal Diseases 2Bone Marrow Neoplasms 2Wilms Tumor 1Vitamin D Deficiency 1Vascular Diseases 1

Interventions

Lenalidomide 2Dexamethasone 2Bortezomib 2carfilzomib 1belinostat 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Bone Marrow Neoplasms × Lenalidomide × Plasma cell × Clear all
NCT03859427 2024-08-13

ARROW2

Amgen

Phase 3 Completed
454 enrolled 24 charts
Plasma cell

Multiple Myeloma, Recurrence, Bone Marrow Neoplasms

NCT00908232 2015-01-15

SEQUENTIAL

Janssen-Cilag International NV

Phase 2 Completed
163 enrolled 11 charts
Plasma cell

Multiple Myeloma, Disease Progression, Bone Marrow Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡